Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 20/06/2022
• Auteurs : Ewen MullinsJean‐louis BressonTamas DalmayIan Crawford DewhurstMichelle M EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoFrancisco Javier MorenoHanspeter NaegeliFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiTilemachos GoumperisTommaso Raffaello
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Résumé : Genetically modified (GM) soybean 40-3-2 expresses a 5-enolpyruvylshikimate-3-phosphate synthase protein from Agrobacterium sp. strain CP4 (CP4 EPSPS), which confers tolerance to glyphosate. This event was previously assessed by the GMO Panel as a single event and as part of a two-event stack and was found to be as safe as its conventional counterparts and other appropriate comparators with respect to potential effects on human and animal health and the environment. On September 2021, the European Commission requested EFSA to evaluate a new bioinformatics study which revealed predicted genomic deletions at the insertion sites using the available soybean reference genome. Considering the variability of the soybean genome, with a number of structural variants such as presence/absence variants and copy number variants including genic regions, as well as the fact that a number of genes are present only in particular varieties, the GMO Panel concludes that comparing only to the reference genome does not allow to conclude that the transformation event resulted in gene loss. In support of this, the transcriptomic analysis did not show major differences in gene expression when comparing the soybean 40-3-2 with the most closely related conventional variety, indicating that the genetic redundancy may compensate for the potential gene loss. Moreover, the composition, phenotypic and agronomic analyses already assessed by the GMO Panel in previous opinions did not show differences between soybean 40-3-2 and its comparators suggesting that the potential gene loss may not have a significant phenotypic effect in soybean 40-3-2. For these reasons, the EFSA GMO Panel concludes that the new information provided by the applicant on soybean 40-3-2 does not alter EFSA's previous conclusions.

---

Fichiers liés : EFSA Journal - 2022 - - Risk assessment of a new bioinformatics evaluation of the insertion sites of genetically modified.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 20/06/2022
• Auteurs : Ewen MullinsJean‐louis BressonTamas DalmayIan Crawford DewhurstMichelle M EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoFrancisco Javier MorenoHanspeter NaegeliFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiMichele ArdizzoneGiacomo de SanctisSilvia FedericiAntonio Fernandez DumontAndrea GennaroJose Angel Gomez RuizTilemachos GoumperisAnna LanzoniPaolo LenziFranco Maria NeriNikoletta PapadopoulouTommaso RaffaelloFranz Streissl
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Résumé : Assessment of genetically modified oilseed rape MON 94100 for food and feed uses, under regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2020-169) EFSA Panel on Genetically Modified Organisms (GMO),

---

Fichiers liés : EFSA Journal - 2022 - - Assessment of genetically modified oilseed rape MON 94100 for food and feed uses under regulation.pdf

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 19/06/2022
• Auteurs : Boris JungClément Le BihanPierre PortalesNathalie BourgeoisThierry VincentLaurence LachaudGerald ChanquesMatthieu ConseilPhilippe CornePablo MassanetJean François TimsitSamir Jaber
• Organismes : Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire de Nîmes Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]

---

Résumé : Background : Precision medicine risk stratification is desperately needed to both avoid systemic antifungals treatment delay and over prescription in the critically ill with risk factors. The aim of the present study was to explore the combination of host immunoparalysis biomarker (monocyte human leukocyte antigen-DR expression (mHLA-DR)) and Candida sp wall biomarker β-d-glucan in risk stratifying patients for secondary invasive Candida infection (ICI). Methods : Prospective observational study. Two intensive care units (ICU). All consecutive non-immunocompromised septic shock patients. Serial blood samples (n=286) were collected at day 0, 2 and 7 and mHLA-DR and β-d-glucan were assayed. Secondary invasive Candida sp infection occurrence were then followed. Results : Fifty patients were included, 42 (84%) had a Candida score equal or greater than 3 and 10 patients developed a secondary invasive Candida sp infection. ICU admission mHLA-DR expression and β-d-glucan (BDG) failed to predict secondary invasive Candida sp infection. Time-dependent cause-specific hazard ratio of ICI was 6.56[1.24-34.61] for mHLA-DR < 5000 Ab/c and 5.25[0.47-58.9] for BDG > 350pg/mL. Predictive negative value of mHLA-DR > 5000 Ab/c and BDG > 350 pg/mL combination at day 7 was 81% [95%CI 70-92]. Conclusion : This proof of concept study suggests that mHLA-DR predicts ICI in high risk patients with septic shock. The added value of BDG and other fungal tests should be regarded according to the host immune function markers. Trial registration: ClinicalTrials.gov identifier: NCT03136081 Take home message : Combination of monocytic HLA-DR expression and beta-D-glucan in patients hospitalized for septic shock failed to predict invasive candida infection but could be useful to rule out infection.

---

Fichiers liés : 2020 Jung et al., Combination.pdf

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 17/06/2022
• Auteurs : Pierre MarionAdeline FermanianGérard BiauJean-Philippe Vert
• Organismes : Laboratoire de Probabilités, Statistique et Modélisation Centre de Bioinformatique Laboratoire de Probabilités, Statistique et Modélisation Google Brain, Paris

---

Résumé : Deep ResNets are recognized for achieving state-of-the-art results in complex machine learning tasks. However, the remarkable performance of these architectures relies on a training procedure that needs to be carefully crafted to avoid vanishing or exploding gradients, particularly as the depth L increases. No consensus has been reached on how to mitigate this issue, although a widely discussed strategy consists in scaling the output of each layer by a factor α_L. We show in a probabilistic setting that with standard i.i.d. initializations, the only non-trivial dynamics is for α_L = 1 / √ L (other choices lead either to explosion or to identity mapping). This scaling factor corresponds in the continuous-time limit to a neural stochastic differential equation, contrarily to a widespread interpretation that deep ResNets are discretizations of neural ordinary differential equations. By contrast, in the latter regime, stability is obtained with specific correlated initializations and α_L = 1 / L. Our analysis suggests a strong interplay between scaling and regularity of the weights as a function of the layer index. Finally, in a series of experiments, we exhibit a continuous range of regimes driven by these two parameters, which jointly impact performance before and after training.

---

Fichiers liés : sample.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 17/06/2022
• Auteurs : Mélusine DurandNicolas NagotLaurent MichelSao Mai LeHuong Duong ThiR. ValloAmélie VizeneuxDelphine RapoudHoang Thi GiangCatherine QuilletNham Thi Tuyet ThanhKhuat Thi Hai OanhVinh Vu HaiJonathan FeelemyerPhilippe van de PerrePham Minh KhueDidier LaureillardDon C Des JarlaisJean-Pierre Moles
• Organismes : Pathogenesis and Control of Chronic and Emerging Infections Université des Antilles Etablissement français du don du sang [Montpellier] Université des Antilles Pathogenesis and Control of Chronic and Emerging Infections Etablissement français du don du sang [Montpellier] Centre de recherche en épidémiologie et santé des populations Dpt of Public Health [Hai Phong] Dpt of Public Health [Hai Phong] Pathogenesis and Control of Chronic and Emerging Infections Université des Antilles Etablissement français du don du sang [Montpellier] Université des Antilles Pathogenesis and Control of Chronic and Emerging Infections Etablissement français du don du sang [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections Université des Antilles Etablissement français du don du sang [Montpellier] Dpt of Public Health [Hai Phong] Pathogenesis and Control of Chronic and Emerging Infections Université des Antilles Etablissement français du don du sang [Montpellier] Viet Tiep Hospital [Hai Phong, Vietnam] College of Global Public Health [New York] Pathogenesis and Control of Chronic and Emerging Infections Université des Antilles Etablissement français du don du sang [Montpellier] Dpt of Public Health [Hai Phong] Pathogenesis and Control of Chronic and Emerging Infections Hôpital Universitaire Carémeau [Nîmes] Université des Antilles Etablissement français du don du sang [Montpellier] New York University [New York] Pathogenesis and Control of Chronic and Emerging Infections Université des Antilles Etablissement français du don du sang [Montpellier]
• Publié dans Frontiers in Psychiatry le 30/10/2020

---

Résumé : Premature biological aging, assessed by shorter telomere length (TL) and mitochondrial DNA (mtDNA) alterations, has been reported among people with major depressive disorders or psychotic disorders. However, these markers have never been assessed together among people who inject drugs (PWIDs), although mental disorders are highly prevalent in this population, which, in addition, is subject to other aggravating exposures. Diagnosis of mental disorders was performed by a psychiatrist using the Mini International Neuropsychiatric Interview test among active PWIDs in Haiphong, Vietnam. mtDNA copy number (MCN), mtDNA deletion, and TL were assessed by quantitative PCR and compared to those without any mental disorder. We next performed a multivariate analysis to identify risk factors associated with being diagnosed with a major depressive episode (MDE) or a psychotic syndrome (PS). In total, 130 and 136 PWIDs with and without psychiatric conditions were analyzed. Among PWIDs with mental disorders, 110 and 74 were diagnosed with MDE and PS, respectively. TL attrition was significantly associated with hepatitis C virus-infected PWIDs with MDE or PS (adjusted odds ratio [OR]: 0.53 [0.36; 0.80] and 0.59 [0.39; 0.88], respectively). TL attrition was even stronger when PWIDs cumulated at least two episodes of major depressive disorders. On the other hand, no difference was observed in mtDNA alterations between groups. The telomeric age difference with drug users without a diagnosis of psychiatric condition was estimated during 4.2-12.8 years according to the number of MDEs, making this group more prone to age-related diseases.

---

Fichiers liés : Frontiers_in_Psychiatry_10.3389.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 17/06/2022
• Auteurs : Christelle BruniMuath AlkadiJean-Noël CaylaIryna ChaikovskaSophie ChancéVincent ChaumatOlivier DalifardNicolas DelerueKevin DuprazMohamed El KhaldiNoureddine El KamchiEzgi ErgenlikPhilippe GauronAlexandre GonninEmmanuel GoutierreHayg GulerMarie JacquetViacheslav KubytskyiPierre LepercqFrederic Letellier-CohenJean Claude MarruchoBruno MercierEric MistrettaHugues MonardAlexandre MoutardierMaher OmeichV. SoskovFrancois Wicek
• Organismes : Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie

---

Résumé : The ThomX accelerator beam commissioning phase is now ongoing. The 50 MeV electron accelerator complex consists of a 50 MeV linear accelerator and a pulsed mode ring. It is dedicated to the production of X-rays by Compton backscattering. The performance of the beam at the interaction point is demanding in terms of emittance, charge, energy spread and transverse size. The choice of an undamped ring in pulsed mode also stresses the performance of the beam from the linear accelerator. Thus, commissioning includes a beam based alignment and a simulation/experimental matching procedure to reach the X-ray beam requirements. We will present the first 50 MeV electron beam obtained with ThomX and its characteristics.

---

Fichiers liés : weoysp2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 16/06/2022
• Auteurs : Cendrine GodetFrancis CouturaudSylvain Marchand-AdamChristophe PisonF. GagnadouxElodie BlanchardCamille TailléBruno PhilippeSandrine HirschiClaire AndréjakArnaud BourdinCécile ChenivesseStéphane DominiqueLaurence BassinetMarlène Murris-EspinFrédéric RivièreGilles GarciaDenis CaillaudFrançois-Xavier BlancFrançois GoupilAnne BergeronAnne GondouinJean-Pierre FratThomas FlamentBoubou CamaraPascaline PriouAnne-Laure BrunFrançois LaurentStéphanie RagotJacques Cadranel
• Organismes : AP-HP - Hôpital Bichat - Claude Bernard [Paris] Université de Brest Département de Médecine Interne et Pneumologie [Brest] Centre Hospitalier Régional Universitaire de Tours Université de Tours Centre Hospitalier Universitaire [CHU Grenoble] Université Grenoble Alpes Centre Hospitalier Universitaire d'Angers Hôpital Haut-Lévêque [CHU Bordeaux] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Physiopathologie et Epidémiologie des Maladies Respiratoires Centre Hospitalier René Dubos [Pontoise] Hôpitaux Universitaires de Strasbourg CHU Amiens-Picardie Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [CHU Lille] Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 CHU Rouen Centre Hospitalier Intercommunal de Créteil Service de pneumologie [Toulouse] Hôpital d'instruction des Armées Percy Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hypertension pulmonaire : physiopathologie et innovation thérapeutique Université Clermont Auvergne Service Pneumologie / Allergologie [CHU Clermont-Ferrand] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Le Mans (CH Le Mans) Hopital Saint-Louis [AP-HP] Service de Pneumologie, oncologie thoracique et allergologie respiratoire [CHRU Besançon] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Universitaire [CHU Grenoble] Université Grenoble Alpes Centre Hospitalier Universitaire d'Angers Hôpital Foch [Suresnes] Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) CHU Tenon [AP-HP]
• Publié dans European Respiratory Journal le 23/10/2020

---

Résumé : Background In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised antifungal treatment may be a strategy for maintaining remission. Methods We performed a randomised, single-blind, clinical trial in 30 centres. Patients with controlled ABPA after a 4-month attack treatment (corticosteroids and itraconazole) were randomly assigned to nebulised liposomal-amphotericin-B or placebo for 6 months. The primary outcome was occurrence of a first severe clinical exacerbation within 24 months following randomisation. Secondary outcomes included the median time-to-first severe clinical exacerbation, number of severe clinical exacerbations per patient, ABPA-related biological parameters. Results Among 174 enrolled patients with ABPA from March 2015 through July 2017, 139 were controlled after 4-month attack treatment and were randomised. The primary outcome occurred in 33 (50.8%) of 65 patients in nebulised liposomal-amphotericin-B group and 38 (51.3%) of 74 in placebo group (absolute difference −0.6%, 95% CI −16.8% to +15.6%, odds ratio 0.98, 95% CI 0.50 to 1.90; p=0.95). The median time-to-first severe clinical exacerbation was longer in liposomal-amphotericin-B group, 337 days (IQR, 168 to 476) versus 177 (64 to 288). At the end of maintenance therapy, total immunoglobulin-E and Aspergillus precipitins were significantly decreased in nebulised liposomal-amphotericin-B group. Conclusions In ABPA, maintenance therapy using nebulised liposomal-amphotericin-B did not reduce the risk of severe clinical exacerbation. The presence of some positive secondary outcomes creates clinical equipoise for further research.

---

Fichiers liés : 2022 Godet et al., Nebulised.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 15/06/2022
• Auteurs : Benoit MauvieuxCorentin HingrandJoffrey DrignyAmir HodzicPauline BaronRémy HurdielRomain JouffroyJean‐charles VauthierMathias PessiglioneAntonius WiehlerFrancis DegacheSébastien PavaillerElsa HeymanMathilde PlardPhilippe NoirezBlaise DuboisJean François EsculierAnh Phong NguyenJoachim van CantOlivier Roy BaillargeonBenoît Pairot de FontenayPierre Louis DelaunayStéphane Besnard
• Organismes : Mobilités : Vieillissement, Pathologie, Santé Mobilités : Vieillissement, Pathologie, Santé Mobilités : Vieillissement, Pathologie, Santé Mobilités : Vieillissement, Pathologie, Santé Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 Université du Littoral Côte d'Opale Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 Université du Littoral Côte d'Opale Hôpital Necker - Enfants Malades [AP-HP] Institut de recherche biomédicale et d’épidémiologie du sport Centre de recherche en épidémiologie et santé des populations Université de Lorraine Institut du Cerveau = Paris Brain Institute Institut du Cerveau = Paris Brain Institute Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 Espaces et Sociétés Performance, Santé, Métrologie, Société - EA 7507 Université Catholique de Louvain = Catholic University of Louvain Laboratoire Interuniversitaire de Biologie de la Motricité Mobilités : Vieillissement, Pathologie, Santé Vertige Extrême
• Publié dans JMIR Research Protocols le 25/10/2020

---

Résumé : Background The growing interest of the scientific community in trail running has highlighted the acute effects of practice at the time of these races on isolated aspects of physiological and structural systems; biological, physiological, cognitive, and muscular functions; and the psychological state of athletes. However, no integrative study has been conducted under these conditions with so many participants and monitoring of pre-, per-, and postrace variables for up to 10 days over a distance close to 100 miles. Objective The aim of this study was to evaluate the kinetics of the performance parameters during a 156 km trail run and 6000 m of elevation gain in pre-, per-, and postrace conditions. The general hypothesis is based on significant alterations in the psychological, physiological, mechanical, biological, and cognitive parameters. Methods The Trail Scientifique de Clécy took place on November 11, 2021. This prospective experimental study provides a comprehensive exploration of the constraints and adaptations of psychophysiological and sociological variables assessed in real race conditions during a trail running of 156 km on hilly ground and 6000 m of elevation gain (D+). The study protocol allowed for repeatability of study measurements under the same experimental conditions during the race, with the race being divided into 6 identical loops of 26 km and 1000 m D+. Measurements were conducted the day before and the morning of the race, at the end of each lap, after a pit stop, and up to 10 days after the race. A total of 55 participants were included, 43 (78%) men and 12 (22%) women, who were experienced in ultra–trail-running events and with no contraindications to the practice of this sport. Results The launch of the study was authorized on October 26, 2021, under the trial number 21-0166 after a favorable opinion from the Comité de Protection des Personnes Ouest III (21.09.61/SIRIPH 2G 21.01586.000009). Of the 55 runners enrolled, 41 (75%) completed the race and 14 (25%) dropped out for various reasons, including gastric problems, hypothermia, fatigue, and musculoskeletal injuries. All the measurements for each team were completed in full. The race times (ie, excluding the measurements) ranged from 17.8206 hours for the first runner to 35.9225 hours for the last runner. The average time to complete all measurements for each lap was 64 (SD 3) minutes. Conclusions The Trail Scientifique de Clécy, by its protocol, allowed for a multidisciplinary approach to the discipline. This approach will allow for the explanation of the studied parameters in relation to each other and observation of the systems of dependence and independence. The initial results are expected in June 2022. International Registered Report Identifier (IRRID) RR1-10.2196/38027

---

Fichiers liés : Study of the Kinetics of the Determinants of Performance During a Mountain Ultramarathon- Multidisciplinary Protocol of the First Trail Scientifique de Clécy 2021.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 14/06/2022
• Auteurs : Clément MabireRomane GuilbaudJorge DuarteAude DarracqAli PiraniHélène RimbertDelphine MadurClémentine VitteNathalie RivièreValérie CombesJean-Philippe PichonPierre DubreuilLaurence MoreauJohann JoetsAlain CharcossetJulie FievetStéphane Nicolas
• Organismes : Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) BIOGEMMA Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) Affymetrix BIOGEMMA Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) BIOGEMMA Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) BIOGEMMA BIOGEMMA Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale) Génétique Quantitative et Evolution - Le Moulon (Génétique Végétale)

---

Source

---

• Type de publi. : Ouvrage (y compris édition critique et traduction)
• Date de publi. : 14/06/2022
• Auteurs : Stéphane CaporalPierre Esplugas-LabatutPhilippe SégurSylvie Torcol
• Organismes : Centre de Recherches Critiques sur le Droit Université Jean Monnet - Saint-Étienne

---

Source